Search the Newsreel

JHS Svendgaard Retail Ventures reports standalone net profit of Rs 0.24 crore in the June 2026 quarter

JHS Svendgaard Retail Ventures subscribes to ₹5 Cr OCDs of Purple Rock Infra

JHS Svendgaard Retail appoints Sood and Pathak as independent directors

JHS Svendgaard Q1 Results: Net profit rises 156% YoY to ₹24 lakh

JHS Svendgaard Retail Ventures: Q1 ਵਿੱਚ ਮੁਨਾਫਾ, ਵਿੱਤੀ ਸੁਧਾਰਾਂ ਨੂੰ ਮਨਜ਼ੂਰੀ

JHS Svendgaard Retail Ventures Posts Q1 Profit, Approves Financial Rectifications

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics reported its second-quarter 2026 financial results, highlighting $73.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which is expected to fund operations into late 2027. The company is actively assessing unblinded Phase 3 HERO and OLE data …

JHS Svendgaard Retail Ventures accepts Dr. Deepali Bhardwaj resignation

Why is Aardvark Therapeutics stock surging today?

Aardvark Therapeutics stock surged 11.1% in pre-open trading after reporting better-than-expected Q2 2026 financial results, beating EPS estimates by $0.21. The company also announced a stronger cash position extending into late 2027 and ongoing positive discussions with the FDA regarding its ARD-101 program, all …

JHS Svendgaard Laboratories consolidated net profit rises 2.83% in the June 2026 quarter

Aardvark Therapeutics Q2 Results: Net loss flat at $14.4 million

Aardvark Therapeutics reported a Q2 EPS of $(0.66), surpassing analyst estimates of $(0.91), while its net loss remained flat at $14.4 million compared to the previous year. This performance was largely due to reduced R&D expenses after the halting of ARD-101 trials, although partially …

Form 8K Aardvark Therapeutics Inc For: 11 August By Investing.com

This article reports on the filing of a Form 8K by Aardvark Therapeutics Inc. for August 11. The filing is a standard regulatory disclosure document that companies submit to the SEC. The article lists the company's stock symbol as AARD.

Aardvark Therapeutics (AARD) faces ARD-101 clinical hold but retains $73.9M cash

Aardvark Therapeutics reported a net loss of $14.4 million for Q2 2026 and $36.0 million for the first six months of 2026, driven by R&D and public-company overhead, but maintains $73.9 million in cash, cash equivalents, and short-term investments, expected to fund operations into …

Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Aardvark Therapeutics (NASDAQ:AARD) announced its quarterly earnings, reporting a loss of $0.66 per share, which surpassed analyst expectations of a $0.87 loss by $0.21. Despite beating estimates, the company's shares fell by 4.9% to $7.19 during Tuesday trading. Institutional investors have increased their stakes, …

Aardvark Therapeutics Reports Q2 2026 Results, Updates ARD-101 PWS Program and FDA Discussions

Aardvark Therapeutics announced its Q2 2026 financial results, reporting a net loss of $14.4 million and a cash position of $73.9 million, sufficient to fund operations into late 2027. The company is actively engaging with the FDA to resolve a clinical hold on its …

Aardvark to Assess Unblinded Prader-Willi Trial Data in Q3 2026

Aardvark Therapeutics reported its second-quarter 2026 financial results, revealing $73.9 million in cash and short-term investments, which is expected to fund operations into late 2027. The company is currently assessing unblinded Phase 3 HERO and OLE trial data for ARD-101 in Prader-Willi syndrome in …

Aardvark Therapeutics, Inc. Q2 2026: Net loss $14.4M, EPS $(0.66) — 10-Q Summary

Aardvark Therapeutics, Inc. reported a net loss of $14.4 million, or $(0.66) per diluted share, for Q2 2026, consistent with the prior year. Cash and cash equivalents increased to $73.8 million. Clinical trials for ARD-101 and ARD-201 were paused due to cardiac observations, leading …

JHS Svendgaard turns profitable in Q1FY26 on revenue surge

JHS Svendgaard Laboratories Q1 Results: Net profit turns positive at ₹109 lakh

Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview

Aardvark Therapeutics, Inc. is projected to report a loss of 87 cents per share in its upcoming earnings. This information comes from a Refinitiv earnings preview. The full article content is accessible via TradingView, which provides news from various sources including Reuters.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Hold" by Brokerages

AARD|Aardvark Therapeutics Inc|Price:6.600|Chg%:+0.200

This article provides a detailed financial overview of Aardvark Therapeutics Inc (AARD), including real-time quotes, key financial figures, and market trends. It highlights the company's current stock performance, analyst ratings indicating a "Buy" with a target price of $14.00, and a company overview focusing …

JHS Svendgaard shareholders approve fund modification with 99.9% support

Aardvark shares plunge 32% after FDA halts clinical trial for Prader-Willi Syndrome drug.

Aardvark Therapeutics' stock dropped 32% after the FDA placed a clinical hold on its Prader-Willi Syndrome drug, ARD-101, due to serious safety concerns, following a previous 56% decline when its Phase 3 trial was halted for similar reasons. An investigation has been launched into …

Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman

Hagens Berman is continuing its investigation into Aardvark Therapeutics (AARD) after the FDA placed a clinical hold on its lead drug candidate, ARD-101, for Prader-Willi Syndrome. This follows a previous 56% stock drop when Aardvark paused its HERO trial due to serious safety risks, …

Aardvark Therapeutics Market Sentiment

This article analyzes market sentiment for Aardvark Therapeutics (AARD) based on analyst consensus, short interest, options flow, and recent insider activity. Key signals show a "Buy" consensus from analysts, 3.7% short interest, and a 0.00 Put/Call ratio indicating more bullish calls. The article provides …

Aardvark Therapeutics Inc (AARD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aardvark Therapeutics Inc (AARD), detailing various indicators and moving averages. It offers a snapshot of current buy, sell, and neutral signals for both technical indicators and moving averages to help investors make informed decisions. The analysis emphasizes …

Aardvark Therapeutics Inc (AARD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Aardvark Therapeutics Inc (AARD), focusing on metrics like PE and PB ratios. It indicates the current stock price and market capitalization. The content is from TradingKey and includes an overview of the company's financial data and discussions.

Aardvark Therapeutics Inc (AARD) Balance Sheet

This article provides the quarterly and annual balance sheets for Aardvark Therapeutics Inc (AARD), enabling evaluation of its financial health through key metrics. Investors can analyze liquidity, leverage, and return on equity using detailed financial data such as cash, assets, liabilities, and shareholders' equity. …

Aardvark Therapeutics Inc (AARD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Aardvark Therapeutics Inc (AARD), listing major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over recent quarters, and changes in stakes by notable investors. The data shows Decheng Capital LLC as the …

Aardvark Therapeutics Inc (AARD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Aardvark Therapeutics Inc (AARD) Income Statement

US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead

Aardvark Therapeutics Inc. (AARD:NASDAQ) has been placed on full clinical hold by the FDA for its lead asset, ARD-101, for hyperphagia in Prader-Willi Syndrome, leading to a reiterated Neutral rating and a US$6.00 price target from H.C. Wainwright & Co. The company plans to …